Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference
Adverum Biotechnologies (Nasdaq: ADVM) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adverum Biotechnologies (Nasdaq: ADVM) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. The company focuses on addressing unmet medical needs in ocular and rare diseases. A video webcast of their presentation will be available on demand starting at 10:00 am ET today and can be accessed for 30 days on their website. Adverum is advancing its gene therapy candidate, ADVM-022, aimed at treating wet age-related macular degeneration and diabetic macular edema.
Positive
- Participation in a significant healthcare conference may enhance visibility and investor interest.
- Advancement of gene therapy candidate ADVM-022 showcases commitment to addressing serious ocular diseases.
Negative
- None.
Details
News Market Reaction – ADVM
The recorded move for ADVM in the trading session of this news was +7.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
Adverum’s video webcast will be accessible on demand beginning today at 10:00 am ET under Events and Presentations in the Investors section of the company's website. This webcast will be available on the Adverum website for 30 days.
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.